Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia

Mohammed Alasseiri, Afsar U. Ahmed, Bryan R.G. Williams

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Integrin-linked kinase (ILK) has emerged as a critical adaptor and mediator protein in cell signaling pathways that is commonly deregulated in acute myeloid leukemia (AML). This has led to the expectation that therapeutic targeting of ILK may be a useful option in treating leukemia. Although ILK can regulate many cellular processes, including cell differentiation, survival, migration, apoptosis and production of pro-inflammatory cytokines, its role in promoting AML is still unclear. However, its ability to mediate phosphorylation and regulate the important hematopoietic stem cell regulators protein kinase B (AKT) and glycogen synthase kinase-3β supports ILK as an attractive target for the development of novel anticancer therapeutics. In this review, we summarize the existing knowledge of ILK signaling and its impact on cytokines, paying particular attention to the relevance of ILK signaling in AML. We also discuss the rationale for targeting ILK in the treatment of AML and conclude with perspectives on the future of ILK-targeted therapy in AML.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCytokine and Growth Factor Reviews
Volume43
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • Acute myeloid leukemia
  • Cell signaling
  • Cytokines
  • Hematopoiesis
  • Integrin-linked kinase
  • Therapeutics

Cite this

@article{c9cc920a80a6456e95371d75bcd78ce0,
title = "Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia",
abstract = "Integrin-linked kinase (ILK) has emerged as a critical adaptor and mediator protein in cell signaling pathways that is commonly deregulated in acute myeloid leukemia (AML). This has led to the expectation that therapeutic targeting of ILK may be a useful option in treating leukemia. Although ILK can regulate many cellular processes, including cell differentiation, survival, migration, apoptosis and production of pro-inflammatory cytokines, its role in promoting AML is still unclear. However, its ability to mediate phosphorylation and regulate the important hematopoietic stem cell regulators protein kinase B (AKT) and glycogen synthase kinase-3β supports ILK as an attractive target for the development of novel anticancer therapeutics. In this review, we summarize the existing knowledge of ILK signaling and its impact on cytokines, paying particular attention to the relevance of ILK signaling in AML. We also discuss the rationale for targeting ILK in the treatment of AML and conclude with perspectives on the future of ILK-targeted therapy in AML.",
keywords = "Acute myeloid leukemia, Cell signaling, Cytokines, Hematopoiesis, Integrin-linked kinase, Therapeutics",
author = "Mohammed Alasseiri and Ahmed, {Afsar U.} and Williams, {Bryan R.G.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.cytogfr.2018.06.001",
language = "English",
volume = "43",
pages = "1--7",
journal = "Cytokine and Growth Factor Reviews",
issn = "1359-6101",
publisher = "Pergamon",

}

Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia. / Alasseiri, Mohammed; Ahmed, Afsar U.; Williams, Bryan R.G.

In: Cytokine and Growth Factor Reviews, Vol. 43, 01.10.2018, p. 1-7.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Mechanisms and consequences of constitutive activation of integrin-linked kinase in acute myeloid leukemia

AU - Alasseiri, Mohammed

AU - Ahmed, Afsar U.

AU - Williams, Bryan R.G.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Integrin-linked kinase (ILK) has emerged as a critical adaptor and mediator protein in cell signaling pathways that is commonly deregulated in acute myeloid leukemia (AML). This has led to the expectation that therapeutic targeting of ILK may be a useful option in treating leukemia. Although ILK can regulate many cellular processes, including cell differentiation, survival, migration, apoptosis and production of pro-inflammatory cytokines, its role in promoting AML is still unclear. However, its ability to mediate phosphorylation and regulate the important hematopoietic stem cell regulators protein kinase B (AKT) and glycogen synthase kinase-3β supports ILK as an attractive target for the development of novel anticancer therapeutics. In this review, we summarize the existing knowledge of ILK signaling and its impact on cytokines, paying particular attention to the relevance of ILK signaling in AML. We also discuss the rationale for targeting ILK in the treatment of AML and conclude with perspectives on the future of ILK-targeted therapy in AML.

AB - Integrin-linked kinase (ILK) has emerged as a critical adaptor and mediator protein in cell signaling pathways that is commonly deregulated in acute myeloid leukemia (AML). This has led to the expectation that therapeutic targeting of ILK may be a useful option in treating leukemia. Although ILK can regulate many cellular processes, including cell differentiation, survival, migration, apoptosis and production of pro-inflammatory cytokines, its role in promoting AML is still unclear. However, its ability to mediate phosphorylation and regulate the important hematopoietic stem cell regulators protein kinase B (AKT) and glycogen synthase kinase-3β supports ILK as an attractive target for the development of novel anticancer therapeutics. In this review, we summarize the existing knowledge of ILK signaling and its impact on cytokines, paying particular attention to the relevance of ILK signaling in AML. We also discuss the rationale for targeting ILK in the treatment of AML and conclude with perspectives on the future of ILK-targeted therapy in AML.

KW - Acute myeloid leukemia

KW - Cell signaling

KW - Cytokines

KW - Hematopoiesis

KW - Integrin-linked kinase

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85048267886&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2018.06.001

DO - 10.1016/j.cytogfr.2018.06.001

M3 - Review Article

VL - 43

SP - 1

EP - 7

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

SN - 1359-6101

ER -